Gabelli Funds LLC Has $9.60 Million Stake in Perrigo Company plc $PRGO

Gabelli Funds LLC increased its stake in Perrigo Company plc (NYSE:PRGO) by 29.8% during the first quarter, Holdings Channel.com reports. The fund owned 893,359 shares of the company’s stock after buying an additional 205,311 shares during the period. Gabelli Funds LLC’s holdings in Perrigo were worth $9,595,000 at the end of the most recent quarter.

A number of other institutional investors have also bought and sold shares of the company. Geneos Wealth Management Inc. boosted its position in shares of Perrigo by 439.1% during the 1st quarter. Geneos Wealth Management Inc. now owns 965 shares of the company’s stock valued at $27,000 after purchasing an additional 786 shares in the last quarter. Kestra Investment Management LLC grew its position in Perrigo by 57.1% in the 2nd quarter. Kestra Investment Management LLC now owns 1,766 shares of the company’s stock valued at $47,000 after purchasing an additional 642 shares during the period. EverSource Wealth Advisors LLC increased its position in shares of Perrigo by 116.0% during the fourth quarter. EverSource Wealth Advisors LLC now owns 1,888 shares of the company’s stock worth $26,000 after acquiring an additional 1,014 shares in the last quarter. UMB Bank n.a. increased its holdings in Perrigo by 161.5% during the 4th quarter. UMB Bank n.a. now owns 1,964 shares of the company’s stock worth $27,000 after purchasing an additional 1,213 shares in the last quarter. Finally, Meeder Asset Management Inc. bought a new stake in Perrigo during the fourth quarter worth $28,000. Institutional investors own 95.91% of the company’s stock.

Perrigo Stock Down 0.1%

Perrigo stock opened at $10.08 on Monday. Perrigo Company plc has a 1-year low of $9.23 and a 1-year high of $28.43. The firm has a market capitalization of $1.39 billion, a price-to-earnings ratio of -0.77, a P/E/G ratio of 1.20 and a beta of 0.51. The company has a current ratio of 2.72, a quick ratio of 1.59 and a debt-to-equity ratio of 1.45. The firm has a 50 day simple moving average of $10.60 and a 200 day simple moving average of $11.78.

Perrigo (NYSE:PRGO) last posted its earnings results on Wednesday, May 6th. The company reported $0.43 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.39 by $0.04. Perrigo had a positive return on equity of 9.96% and a negative net margin of 43.50%.The firm had revenue of $841.80 million for the quarter, compared to the consensus estimate of $1.04 billion. During the same quarter in the prior year, the business posted $0.60 earnings per share. The business’s quarterly revenue was down 7.2% on a year-over-year basis. Perrigo has set its FY 2026 guidance at 2.250-2.550 EPS. On average, analysts predict that Perrigo Company plc will post 2.11 earnings per share for the current year.

Perrigo Dividend Announcement

The business also recently disclosed a quarterly dividend, which was paid on Tuesday, June 16th. Investors of record on Friday, May 29th were issued a dividend of $0.29 per share. The ex-dividend date of this dividend was Friday, May 29th. This represents a $1.16 dividend on an annualized basis and a yield of 11.5%. Perrigo’s dividend payout ratio is -8.85%.

Analyst Ratings Changes

A number of equities research analysts have issued reports on PRGO shares. Weiss Ratings raised shares of Perrigo from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Tuesday, July 21st. Zacks Research upgraded shares of Perrigo from a “strong sell” rating to a “hold” rating in a research note on Monday, April 27th. One investment analyst has rated the stock with a Buy rating, four have issued a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, the company has a consensus rating of “Hold” and an average price target of $19.33.

About Perrigo

Perrigo Company plc is a global healthcare supplier specializing in over-the-counter (OTC) and self-care products, as well as generic prescription pharmaceuticals and active pharmaceutical ingredients. The company develops, manufactures and distributes a broad array of consumer health products, including analgesics, vitamins and supplements, digestive health remedies, topical treatments, and infant formulas. Perrigo’s focus on private-label solutions has made it a leading partner for retailers and pharmacy chains seeking high-quality, value-oriented alternatives to branded medications and health supplements.

Organized across three principal business segments—Consumer Healthcare, Prescription Pharmaceuticals and Active Pharmaceutical Ingredients—Perrigo’s operations span research and development, manufacturing, quality assurance and global distribution.